---
document_datetime: 2024-06-07 11:02:32
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/parsabiv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: parsabiv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.1802752
conversion_datetime: 2025-12-21 12:11:56.642926
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Parsabiv

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0023              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 06/06/2024                          | n/a                                         |                                  |           |
| II/0021              | Submission of the final report from study 20170561 listed as a category 3 study in the RMP. This is an                                        | 06/07/2023                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | observational PASS to evaluate the potential association between Parsabiv and gastrointestinal bleeding. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                                  |                                                                                                                                                                                                                                 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0022             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                               | 09/06/2023 | n/a        |                                  |                                                                                                                                                                                                                                 |
| IA/0020             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient             | 05/07/2022 | n/a        |                                  |                                                                                                                                                                                                                                 |
| PSUSA/10533 /202111 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                                              | 10/06/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                               |
| IA/0019             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient             | 12/05/2022 | n/a        |                                  |                                                                                                                                                                                                                                 |
| R/0017              | Renewal of the marketing authorisation.                                                                                                                                                                                                                  | 22/07/2021 | 16/09/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Parsabiv in the approved indication remains favourable and therefore recommended the renewal of the marketing |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                              |            |            |                   | authorisation with unlimited validity. Product Information was updated to incorporate changes introduced during the assessment of the renewal and to align with QRD template version 10.2. The updated RMP has been also submitted (version 3.0).                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10533 /202011 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                                                                                                                                                  | 10/06/2021 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                |
| II/0015             | Update of the SmPC section 4.4 to remove anti- etelcalcetide antibodies testing, minor editorial changes and update of the Product information in line with QRD template v10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                            | 10/12/2020 | 16/09/2021 | SmPC and Annex II | n/a                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10533 /201911 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                                                                                                                                                  | 11/06/2020 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                |
| PSUSA/10533 /201811 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                                                                                                                                                  | 14/06/2019 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                |
| II/0010             | Update of sections 4.8 to add convulsions secondary to hypocalcaemia as uncommon adverse reactions and further information on reports related to hypersensitivity reactions. Editorial correction is made to section 7. The Package Leaflet is updated accordingly. Consequentially, RMP (version 2.1) has been submitted to reclassify some of the existing | 14/02/2019 | 23/09/2019 | SmPC and PL       | Update of section 4.8 of the SmPC, in line with the other calcimimetic agent cinacalcet, by including the Undesirable effect 'convulsions' in SOC nervous system disorders with the frequency uncommon and with a reference to section 4.4. In section 4.4 a reference is made to section 4.8. The Package Leaflet has been updated accordingly. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| IB/0012/G | This was an application for a group of variations. B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size - Change to in-process tests or limits | 20/12/2018 | n/a | B.II.b.5.b applied during |

<div style=\"page-break-after: always\"></div>

|                     | product - Addition of a new test(s) and limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                  |            |            |                 |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10533 /201805 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                            | 29/11/2018 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                          |
| IB/0011             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                              | 05/10/2018 | 23/09/2019 | SmPC            |                                                                                                                                            |
| IB/0009             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                 | 07/09/2018 | n/a        |                 |                                                                                                                                            |
| PSUSA/10533 /201711 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                            | 28/06/2018 | 23/08/2018 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10533/201711. |
| IG/0946             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/06/2018 | 23/07/2018 | PL              |                                                                                                                                            |
| PSUSA/10533 /201705 | Periodic Safety Update EU Single assessment - etelcalcetide                                                                                                                                                                            | 30/11/2017 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                          |
| IG/0853             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                  | 10/11/2017 | 23/07/2018 | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                 |            |            |      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IA/0003 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 07/09/2017 | n/a        |      |
| IB/0001 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                        | 20/07/2017 | 23/07/2018 | SmPC |